Janus

EQS-News: Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Janus, Biotechnology, Conference, MRI, Serum, Histology, Regeneration, PMS, Multiple sclerosis, Woman, Disease, Calcium, Clinical trial, Investment, AFL, SIRT6, Medicinal chemistry, Ulcerative colitis, Biomarker, Journal of Medicinal Chemistry, DHODH, Patient, Journal, RMS, Magnetic resonance imaging, Pharmaceutical industry

“With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.

Key Points: 
  • “With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.
  • A more thorough review of recent events and upcoming milestones follows:
    Announced a three-tranche private placement of up to $240 million with participation from select new and existing investors today.
  • Immunic believes that this data illustrates biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Immunic believes this data provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture.

EQS-News: Immunic, Inc. Announces Private Placement of up to $240 Million

Retrieved on: 
Friday, January 5, 2024
Janus, Sale, Public expenditure, Clinical trial, SVB Securities, Investment, RTW, Prospectus, Exchange, Exercise, Security (finance)

The first tranche is an upfront payment of $80 million at $1.43 per share, which is expected to close on January 8, 2024, subject to customary closing conditions.

Key Points: 
  • The first tranche is an upfront payment of $80 million at $1.43 per share, which is expected to close on January 8, 2024, subject to customary closing conditions.
  • The third tranche is conditioned on the same volume weighted average share price levels and minimum trading volumes as the second tranche.
  • Leerink Partners is acting as the lead placement agent and Ladenburg Thalmann is acting as a placement agent in connection with the financing.
  • Immunic has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the securities issued in the private placement.

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Janus, Biotechnology, Conference, MRI, Serum, Histology, Regeneration, Entire, PMS, Multiple sclerosis, Woman, Disease, Sirtuin 6, Calcium, Clinical trial, Investment, AFL, SIRT6, Medicinal chemistry, Ulcerative colitis, Biomarker, Journal of Medicinal Chemistry, DHODH, Patient, Journal, RMS, Magnetic resonance imaging, Pharmaceutical industry

"With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.

Key Points: 
  • "With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.
  • A more thorough review of recent events and upcoming milestones follows:
    Announced a three-tranche private placement of up to $240 million with participation from select new and existing investors today.
  • Immunic believes that this data illustrates biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Immunic believes this data provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture.

Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24

Retrieved on: 
Thursday, January 4, 2024
Janus, Commercialization, OD, Drug development, Completeness, CMO, Hepatocyte growth factor, Master of Science, Novo Holdings A/S, Ear, MD, Neurotrophic factors, Nerve, Mass, Burns (surname), Mouth ulcer, Perforation, Ulcer, Series, Scar, MPH, Patient, NK, Medical imaging

Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.

Key Points: 
  • Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.
  • Oremepermin-α is epitheliotropic, neurotrophic, anti-inflammatory, and anti-fibrotic, suggesting it could be an efficacious and safe option to treat many current unmet needs in diseases of the cornea.
  • Claris expects to complete enrollment in its late-stage multi-center, randomized, double-masked, vehicle-controlled, parallel-group study, with a data readout expected in 1H2024.
  • Additional indications of interest that are being actively pursued by Claris, supported by preclinical and clinical data, include limbal stem cell deficiency and pre-existing corneal scar.

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
Janus, Atopic dermatitis, Receptor (biochemistry), Sanofi, Janus kinase, Hidradenitis suppurativa, Eosinophilic esophagitis, Autoimmunity, Inflammatory bowel disease, HS, Inflammation, Lupus, Blood, TLR, Therapy, Clinical trial, Asthma, JAK, Dupilumab, Roflumilast, Polyp (medicine), TPD, Webcast, Patient, Psoriasis, TYK2, STAT6, Skin, Sinusitis, Pharmaceutical industry

As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.

Key Points: 
  • As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.
  • Kymera will share its immunology strategy, including market insights, program updates, new preclinical data and development timelines, at its virtual R&D Day this morning.
  • In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies.
  • Kymera will host a webcast to discuss its emerging immunology pipeline from 10:00 a.m. – 12:00 p.m.

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Medical Subject Headings, Marketing, JAK2, INN, Immune system, Pigment, ATC, Woman, International, Disease, Language, Mouth, JAK, Acne, European Medicines Agency, Melanocyte, Face, Select, Depigmentation, Patient, JAK1, Diagnosis, Cell, Safety, Anatomy, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Liver, Marketing, PV, INN, Hypertension, Graft-versus-host disease, Polycythemia, Hydroxycarbamide, Infection, Transplant, Splenomegaly, Bruise, Polycythemia vera, Bacteria, Anatomy, IIA, Spleen, Fever, Hypercholesterolemia, Primary myelofibrosis, ATC, Bleeding, Disease, Ageing, JAK, Neutrophil, Blood, System, Disorder, Weight gain, Enzyme, Safety, Anemia, Sepsis, Medical Subject Headings, Agency, B cell, International, Bone pain, Neutropenia, Language, Mouth, Dizziness, Thrombocytopenia, Pancreatic serous cystadenoma, Hypertriglyceridemia, Tablet, Select, Patient, Medicine, Phlebotomy, Hormone, Woman, Weight loss, Headache, Cytomegalovirus, European Medicines Agency, Growth, Janus kinase, Urinary tract infection, Medical device

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Patient, Medical Subject Headings, Marketing, Cytokine, Protein, Human, INN, Infection, ATC, Pharyngitis, International, Nose, Language, Mouth, CPU socket, Inflammation, JAK, European Medicines Agency, Lower respiratory tract infection, PASI, Tablet, Select, Cell, Diagnosis, Janus kinase, TYK2, Anatomy, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Janus International Group Announces Updates to Board of Directors

Retrieved on: 
Tuesday, January 2, 2024
Other Manufacturing, Commercial Building & Real Estate, Technology, Construction & Property, Other Technology, Professional Services, Manufacturing, IOT (Internet of Things), Other Construction & Property, Other Professional Services, Janus, GIP, Stanley Black, Senior, JBI, Partnership, Securitas, Business, GM, University of Minnesota, Bachelor of Arts, Education, University, International Marxist Group, Knowledge, Securitas AB, United States service academies, Engineering, Electrical engineering, Growth, Compensated emancipation, SMC Corporation, MEP, Partner (business rank), Management

The appointments come following the departures of José E Feliciano and Colin Leonard with Clearlake Capital Group, L.P. (“Clearlake”) who have been directors since 2021.

Key Points: 
  • The appointments come following the departures of José E Feliciano and Colin Leonard with Clearlake Capital Group, L.P. (“Clearlake”) who have been directors since 2021.
  • We believe Janus will be well served with the new director leadership going forward.
  • Tony, Joseph, and Eileen bring a wealth of experience in security, finance, cybersecurity, and technology to the Board, and we look forward to their insights and expertise.
  • On behalf of the entire Board, I would like to thank Clearlake for their steadfast partnership and invaluable insights.

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

Retrieved on: 
Tuesday, December 19, 2023
Janus, Disease, Tyrosine kinase inhibitor, Dicarboxylic acid, Antibody, Inflammatory bowel disease, B cell, Gastrointestinal disease, Patent, Integrin, Gastrointestinal tract, SAN, Therapy, JAK, GI, IP, Device, Janus kinase, Peptide, United States patent law, Chemokine, Ulcerative colitis, Pharmaceutical industry

SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .

Key Points: 
  • SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal (GI) disorders through targeted delivery of JAK inhibitors for its NaviCap™ targeted oral delivery platform under development.
  • 17/313,339, entitled “Treatment of a Disease of the Gastrointestinal Tract with a JAK Inhibitor and Devices,” will issue as US Patent No.
  • The patent covers many JAK inhibitors, including those that are approved or in development for a range of indications.